Retinopathy of prematurity: Clinical insights from molecular studies

NeoReviews

Volumn 10, Issue 11, 2009, Pages

  Heidary, Gena ^a   Löfqvist, Chatarina ^b   Mantagos, Iason S ^a   Vanderveen, Deborah K ^a   Hellström, Ann ^b   Smith, Lois E ^b  

^a BOSTON CHILDREN S HOSPITAL   (United States)

^b QUEEN SILVIA CHILDREN'S HOSPITAL   (Sweden)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 77149179512     PISSN: None     EISSN: 15269906     Source Type: Journal    
DOI: 10.1542/neo.10-11-e550     Document Type: Article

References (53)

1. Terry TL. Extreme prematurity and fibroblastic overgrowth of persistent vascular sheath behind each crystalline lens. Am. J Ophthalmol. 1942; 25: 203-204
2. Gilbert C, Foster A. Childhood blindness in the context of VISION 2020-the right to sight. Bull World Health Organ. 2001; 79: 227-232
3. Gilbert C, Muhit M. Twenty years of childhood blindness: what have we learnt? Community Eye Health. 2008; 21: 46-47
4. Gilbert C, Fielder A, Gordillo L, et al; International NO-ROP Group. Characteristics of infants with severe retinopathy of prematurity in countries with low, moderate, and high levels of development: implications for screening programs. Pediatrics. 2005; 115: e518-e525
5. Cryotherapy for Retinopathy of Prematurity Cooperative Group. Multicenter trial of cryotherapy for retinopathy of prematurity: preliminary results. Arch Ophthalmol. 1988; 106: 471-479
6. Shalev B, Farr AK, Repka M.X. Randomized comparison of diode laser photocoagulation versus cryotherapy for threshold retinopathy of prematurity: seven-year outcome. Am. J Ophthalmol. 2001; 132: 76-80
7. Tasman W. Ten-year follow-up from the CRYO-ROP study. Arch Ophthalmol. 2001; 119: 1200-1201
8. Hellström, A, Hård AL, Engström E, et al. Early weight gain predicts retinopathy in preterm infants: new, simple, efficient approach to screening. Pediatrics. 2009; 123: e638-e645
9. Löfqvist C, Andersson E, Sigurdsson J, et al. Longitudinal postnatal weight and insulin-like growth factor I measurements in the prediction of retinopathy of prematurity. Arch Ophthalmol. 2006; 124: 1711-1718
10. Löfqvist C, Andersson E, Sigurdsson J, et al. Validation of a new retinopathy of prematurity screening method monitoring longitudinal postnatal weight and insulinlike growth factor I. Arch Ophthalmol. 2009; 127: 622-627
11. Campbell K. Intensive oxygen therapy as a possible cause of retrolental fibroplasia: a clinical approach. Med J Aust. 1951; 2: 48-50
12. Patz A, Hoeck LE, De La Cruz E. Studies on the effect of high oxygen administration in retrolental fibroplasia. I. Nursery observations. Am. J Ophthalmol. 1952; 35: 1248-1253
13. Smith LE, Wesolowski E, McLellan A, et al. Oxygen-induced retinopathy in the mouse. Invest Ophthalmol Vis Sci. 1994; 35: 101-111
14. Chen J, Smith LE. Retinopathy of prematurity. Angiogenesis. 2007; 10: 133-140
15. Ashton N, Ward B, Serpell G. Effect of oxygen of developing retinal vessels with particular reference to the problem of retrolental fibroplasia. Br J Ophthalmol. 1954; 38: 397-432
16. Tasman W, Patz A, McNamara JA, Kaiser RS, Trese MT, Smith Ophthalmol. 2006; 141: 167-174
17. Smith LE. Pathogenesis of retinopathy of prematurity. Semin Neonatol. 2003; 8: 469-473
18. Lutty GA, Chan-Ling T, Phelps DL, et al. Proceedings of the Third International Symposium on Retinopathy of Prematurity: an update on ROP from the lab to the nursery (November 2003, Anaheim, California). Mol Vis. 2006; 12: 532-580
19. Fortes Filho JB, Bonomo PP, Maia M, Procianoy RS. Weight gain measured at 6 weeks after birth as a predictor for severe retinopathy of prematurity: study with 317 very low birth weight preterm babies. Graefes Arch Clin Exp Ophthalmol. 2009; 247: 831-836
20. Allegaert K, Vanhold C, Casteels I, et al. Perinatal growth characteristics and associated risk of developing threshold retinopathy of prematurity. J AAPOS. 2003; 7: 34-37
21. Bardin C, Zelkowitz P, Papageorgiou A. Outcome of small-for-gestational age and appropriate-for-gestational age infants born before 27 weeks of gestation. Pediatrics. 1997; 100: E4
22. Wallace DK, Kylstra J, Phillips SJ, Hall JG. Poor postnatal weight gain: a risk factor for severe retinopathy of prematurity. J AAPOS. 2000; 4: 343-347
23. Michaelson IC. The mode of development of the vascular system of the retina, with some observations on its significance for certain retinal diseases. Trans Ophthalmol Soc U K. 1948; 68: 137-180
24. Roth AM. Retinal vascular development in premature infants. Am. J Ophthalmol. 1977; 84: 636-640
25. Hughes S, Yang H, Chan-Ling T. Vascularization of the human fetal retina: roles of vasculogenesis and angiogenesis. Invest Ophthalmol. Vis Sci. 2000; 41: 1217-1228
26. Chan-Ling T, McLeod DS, Hughes S, et al. Astrocyte-endothelial cell relationships during human retinal vascular development. Invest Ophthalmol Vis Sci. 2004; 45: 2020-2032
27. Chan-Ling T, Gock B, Stone J. The effect of oxygen on vasoformative cell division. Evidence that "physiological hypoxia" is the stimulus for normal retinal vasculogenesis. Invest Ophthalmol Vis Sci. 1995; 36: 1201-1214
28. Smith LE. Through the eyes of a child: understanding retinopathy through ROP. The Friedenwald lecture. Invest Ophthalmol Vis Sci. 2008; 49: 5177-5182
29. Madan A, Penn JS. Animal models of oxygen-induced retinopathy. Front Biosci. 2003; 8: d1030-d1043
30. Leung DW, Cachianes G, Kuang WJ, Goeddel DV, Ferrara N. Vascular endothelial growth factor is a secreted angiogenic mitogen. Science. 1989; 246: 1306-1309
31. Shweiki D, Itin A, Soffer D, Keshet E. Vascular endothelial growth factor induced by hypoxia may mediate hypoxia-initiated angiogenesis. Nature. 1992; 359: 843-845
32. Pierce EA, Foley ED, Smith LE. Regulation of vascular endothelial growth factor by oxygen in a model of retinopathy of prematurity. Arch Ophthalmol. 1996; 114: 1219-1228
33. Shih SC, Ju M, Liu N, Smith LE. Selective stimulation of VEGFR-1 prevents oxygen-induced retinal vascular degeneration in retinopathy of prematurity. J Clin Invest. 2003; 112: 50-57
34. Pierce EA, Avery RL, Foley ED, Aiello LP, Smith LE. Vascular endothelial growth factor/vascular permeability factor expression in a mouse model of retinal neovascularization. Proc Natl Acad Sci USA.1995; 92: 905-909
35. Aiello LP, Pierce EA, Foley ED, et al. Suppression of retinal neovascularization in vivo by inhibition of vascular endothelial growth factor (VEGF) using soluble VEGF-receptor chimeric proteins. Proc Natl Acad Sci U S A. 1995; 92: 10457-10461
36. Robinson GS, Pierce EA, Rook SL, Foley E, Webb R, Smith LE. Oligodeoxynucleotides inhibit retinal neovascularization in a murine model of proliferative retinopathy. Proc Natl Acad Sci U S A. 1996; 93: 4851-4856
37. Jiang J, Xia XB, Xu HZ, et al. Inhibition of retinal neovascularization by gene transfer of small interfering RNA targeting HIF-1alpha and VEGF. J Cell Physiol. 2009; 218: 66-74
38. Shah PK, Narendran V, Tawansy KA, Raghuram A, Narendran K. Intravitreal bevacizumab (Avastin) for post laser anterior segment ischemia in aggressive posterior retinopathy of prematurity. Indian J Ophthalmol. 2007; 55: 75-76
39. Kong L, Mintz-Hittner HA, Penland RL, Kretzer FL, Chevez-Barrios P. Intravitreous bevacizumab as anti-vascular endothelial growth factor therapy for retinopathy of prematurity: a morphologic study. Arch Ophthalmol. 2008; 126: 1161-1163
40. Mintz-Hittner HA, Kuffel RR Jr. Intravitreal injection of bev-acizumab (avastin) for treatment of stage 3 retinopathy of prematurity in zone I or posterior zone II. Retina. 2008; 28: 831-838
41. Jaquet K, Krause K, Tawakol-Khodai M, Geidel S, Kuck KH. Erythropoietin and VEGF exhibit equal angiogenic potential. Microvasc Res. 2002; 64: 326-333
42. Ribatti D, Vacca A, Roccaro AM, Crivellato E, Presta M. Erythropoietin as an angiogenic factor. Eur J Clin Invest. 2003; 33: 891-896
43. Chen J, Connor KM, Aderman CM, Smith LE. Erythropoietin deficiency decreases vascular stability in mice. J Clin Invest. 2008; 118: 526-533
44. Suk KK, Dunbar JA, Liu A, et al. Human recombinant erythropoietin and the incidence of retinopathy of prematurity: a multiple regression model. J AAPOS. 2008; 12: 233-238
45. Chen J, Smith LE. A double-edged sword: erythropoietin eyed in retinopathy of prematurity. J AAPOS. 2008; 12: 221-222
46. Langford K, Nicolaides K, Miell JP. Maternal and fetal insulin-like growth factors and their binding proteins in the second and third trimesters of human pregnancy. Hum Reprod. 1998; 13: 1389-1393
47. Ong KK, Langkamp M, Ranke MB, et al. Insulin-like growth factor I concentrations in infancy predict differential gains in body length and adiposity: the Cambridge Baby Growth Study. Am J Clin Nutr. 2009; 90: 156-161
48. Lineham JD, Smith RM, Dahlenburg GW, et al. Circulating insulin-like growth factor I levels in newborn premature and full-term infants followed longitudinally. Early Hum Dev. 1986; 13: 37-46
49. Hellström A, Carlsson B, Niklasson A, et al. IGF-I is critical for normal vascularization of the human retina. J Clin Endocrinol Metab. 2002; 87: 3413-3416
50. Hellström A, Perruzzi C, Ju M, et al. Low IGF-I suppresses VEGF-survival signaling in retinal endothelial cells: direct correlation with clinical retinopathy of prematurity. Proc Natl Acad Sci USA.2001; 98: 5804-5808
51. Smith LE, Shen W, Perruzzi C, et al. Regulation of vascular endothelial growth factor-dependent retinal neovascularization by insulin-like growth factor-1 receptor. Nat Med. 1999; 5: 1390-1395
52. Lukiw WJ, Bazan NG. Docosahexaenoic acid and the aging brain. J Nutr. 2008; 138: 2510-2514
53. Connor KM, SanGiovanni JP, Lofqvist C, et al. Increased dietary intake of omega-3-polyunsaturated fatty acids reduces pathological retinal angiogenesis. Nat Med. 2007; 13: 868-873